Primary Aldosteronism

How to Cite This Chapter: Kobza A, Prebtani APH, Rodríguez-Gutiérrez R, Gonzalez-Gonzalez JG, Castillo-Gonzalez DA, Bautista-Orduño KG, Słowińska-Srzednicka J, Płaczkiewicz-Jankowska E. Primary Aldosteronism. McMaster Textbook of Internal Medicine. Kraków: Medycyna Praktyczna. https://empendium.com/mcmtextbook/chapter/B31.II.11.3. Accessed August 15, 2022.
Last Updated: April 13, 2022
Last Reviewed: April 13, 2022
Chapter Information

Definition, Etiology, PathogenesisTop

Primary aldosteronism (PA) is caused by aldosterone hypersecretion that is relatively independent from regulators of its secretion (renin-angiotensin system, intravascular volume, and potassium concentration) and is not suppressed by sodium administration. Aldosterone acts at the distal renal tubule by increasing the reabsorption of Na+ and water and by increasing the excretion of K+ and H+. Excess aldosterone classically leads to the development of hypertension and often, but not always, to hypokalemia. It is one of the most common causes of secondary hypertension and often remains underdiagnosed.

Causes of PA:

1) Most common causes:

a) Aldosterone-producing adenoma (APA), also known as Conn syndrome (30%-40% of patients).

b) Bilateral adrenal hyperplasia (BAH)/idiopathic hyperaldosteronism (IHA) (60%-70% of patients).

2) Less common causes:

a) Unilateral adrenal hyperplasia (UAH).

b) Familial aldosteronism: Type I is caused by the fusion of 2 genes that creates a chimeric gene sensitive to adrenocorticotropic hormone (ACTH) in the adrenal cortex. In such patients administration of dexamethasone (reducing ACTH levels) suppresses aldosterone hypersecretion, which is why this type is also called glucocorticoid-remediable aldosteronism (GRA). Type II refers to a familial aldosterone-producing adenoma, bilateral idiopathic hyperplasia, or both. In such cases the aldosteronism is not ACTH-dependent. The underlying genetic defect has not been identified yet, but it most likely involves the CYP11B2 gene. Type III is caused by a germline mutation of the potassium channel KCNJ5 gene and is associated with severe adrenal hyperplasia and severe manifestations of aldosteronism.

c) Aldosterone-secreting adrenocortical carcinoma (ACC).

Clinical Features and Natural HistoryTop

The major clinical finding is hypertension. Hypokalemia and metabolic alkalosis are present in up to 50% of patients. Rarely patients may have symptoms of hypokalemia and alkalosis, such as muscle weakness, polyuria, excessive thirst, paresthesia, cramps, and tetany.

Patients are typically euvolemic. Edema is uncommon due to an “edema escape” phenomenon, which is probably associated with a compensatory increased secretion of atrial natriuretic peptide (ANP) to maintain proper fluid balance.

Over time, excess aldosterone causes necrosis, fibrosis, and proliferation of myocytes; myocardial hypertrophy; vascular remodeling and fibrosis; and impaired endothelial function. In the kidney it results in damage to small and intermediate arteries and in the development of nephropathy (particularly in the case of increased sodium intake). As a result, there is a greater risk of cardiovascular and renal morbidity and mortality in patients with PA when compared with patients with the same blood pressure (BP) due to essential hypertension. In addition, PA is an independent risk factor for the development of metabolic syndrome and type 2 diabetes mellitus, which further increases cardiovascular risk.

DiagnosisTop

Perform screening in:

1) Patients with refractory hypertension (>140/90 mm Hg) despite treatment with a maximum dose of 3 antihypertensive drugs, including a thiazide or thiazide-like diuretic (and preferably a dihydropyridine calcium channel blocker [DHP-CCB]), or patients requiring ≥4 drugs for adequate BP control.

2) Patients with hypertension and spontaneous hypokalemia ([K+] <3.5 mmol/L) or easily provoked hypokalemia ([K+] <3.0 mmol/L) with a low-dose diuretic.

3) Patients with hypertension and discovered adrenal incidentaloma.

4) Patients with hypertension aged <20 years or patients with hypertension and first-degree relatives diagnosed with PA or a family history of early-onset hypertension or hemorrhagic stroke at a young age (<40 years).

Diagnostic Tests

1. Basic biochemical tests may reveal:

1) Hypokalemia (may be absent in up to 40% of cases).

2) Normal serum sodium levels approaching the upper limit of normal (ULN) or mild hypernatremia (<150 mEq/L).

3) Mild metabolic alkalosis.

2. Screening hormone tests: Renin, aldosterone, and the aldosterone-to-renin ratio (ARR) are the preferred screening tests, with a low renin level being the most important factor, together with an inappropriately high aldosterone level and a high ARR, to suspect PA, so all 3 parameters need to be taken into account for estimating pretest probability of PA.

The test should be performed after the patient has been ambulatory for 2 hours and is done in the upright position. Hypokalemia should be corrected and sodium should not be restricted prior to testing. Testing can be done while on medications, but if results are inconclusive, and if possible, agents that significantly affect the results (aldosterone antagonists, diuretics) should be stopped 4 to 6 weeks prior to the repeat blood testing and other interfering medications should be withdrawn for 2 weeks (eg, beta-blockers, angiotensin-converting enzyme inhibitors [ACEIs], angiotensin receptor blockers [ARBs], DHP-CCBs, centrally acting alpha2 agonists).

During the washout, BP can be controlled with medications that are much less likely to affect testing, which include alpha1-adrenergic blockers, such as doxazosin, terazosin, prazosin; long-acting non–dihydropyridine calcium channel blockers, such as diltiazem or verapamil; and/or hydralazine.

Interpretation of the ARR depends on the assay and units used (Table 6.1-1).

Medications that can cause false-negative and false-positive results: Table 6.1-2.

When making the decision about testing, it is important to take into account that discontinuing drugs and changing treatment regimens can worsen hypertension and increase the risk of adverse events such as arrhythmias, heart failure, and hypertensive crisis; therefore, caution is needed in those at high risk.

The diagnosis can be made without further confirmatory testing if there is spontaneous hypokalemia, plasma renin below detection levels, and plasma aldosterone concentration (PAC) >555 pmol/L (>20 ng/dL), or if the ARR is >270 pmol/ng (>1400 pmol/L/ng/mL/h) with a PAC >440 pmol/L and a low renin level, or if no spontaneous hypokalemia but a low renin level and a PAC >831 pmol/L are observed. PA is unlikely if the aldosterone level is <139 pmol/L, even with a low renin level.

Mild cortisol cosecretion without overt Cushing syndrome may occur in patients with large APAs (≥1.5 cm) and here it is important to screen for this by measuring a baseline serum dehydroepiandrosterone sulfate (DHEAS) level and performing a 1-mg overnight dexamethasone suppression test.

Confirmatory testing for PA is recommended for all other patients as described below.

3. Confirmatory testing: Perform one of the following to confirm the diagnosis of PA. All tests aim to suppress aldosterone.

1) Salt loading tests (perform either):

a) Oral: Administer >200 mmol/day of oral sodium (ie, equivalent to >5 g/d of sodium, >12 g/day of sodium chloride, or >2 tsp/d of salt) for 3 days. Hypokalemia should be corrected prior the test. Since sodium loading typically increases kaliuresis and hypokalemia, potassium level should be monitored daily and replacement of potassium chloride should be given if needed. PA is defined as a 24-hour urinary aldosterone >33 nmol/day (measured from the morning of day 3 to the morning of day 4). If the result is <28 nmol/day, PA is less likely.

b) Intravenous: Administer 2 L of normal saline IV over 4 hours with the patient in a recumbent or supine position. PA is defined as a postinfusion PAC >280 pmol/L. If PAC is <140 pmol/L, PA is unlikely. Values in between are considered indeterminate. There is newer data that the seated test is more accurate and sensitive than that performed in the recumbent or supine position. Here, PA is defined as a postinfusion PAC >222 pmol/L. If PAC is <171 pmol/L, PA is unlikely. Values in between are considered indeterminate. Cortisol levels are also measured in the seated test before and after infusion to avoid a false-positive elevation in aldosterone concentration at the end of the infusion. These tests are contraindicated in the presence of severe uncontrolled hypertension or congestive heart failure.

2) Captopril suppression test: Administer 25 to 50 mg of captopril orally after the patient has been sitting or standing for 1 hour. While seated, renin and PAC should be measured at time 0 and 1 to 2 hours after ingestion. PA is unlikely if PAC is suppressed by >30% after captopril ingestion. In patients with PA, PAC remains elevated while the renin level remains suppressed.

After confirming the diagnosis of PA, if surgery is an option, it is critical to distinguish a unilateral lesion from BAH/IHA, as treatment options differ. This is usually done in specialized centers.

4. Imaging studies (only to be done after biochemical confirmation due to a high chance of finding an incidentaloma that may be nonfunctional): Computed tomography (CT) allows the visualization of adrenal tumors or abnormal enlargement of 1 segment of an adrenal gland. The patient may still have an APA even if no adrenal tumor is found on CT. If a lesion is found on imaging, it may be a nonfunctioning lesion (eg, nonfunctioning incidentaloma), especially in the elderly; functioning lesion lateralization requires adrenal vein sampling (AVS) (see below). The density of the mass (measured in Hounsfield units [HU]; a mass <10 HU favors a benign pathology), size of the mass, and assessment of the rate of washout of IV contrast allows for differentiating adrenal adenoma (rapid washout) from adrenal carcinoma (usually >4 cm), metastatic lesions, and pheochromocytoma. A CT scan is always recommended as the initial study in patients with PA, as it helps exclude large masses that may represent an adrenocortical carcinoma and aids the surgeon and interventional radiologist where appropriate. Usually magnetic resonance imaging (MRI) has no advantage over CT in subtype evaluation of PA, as it is more expensive and has a lower spatial resolution than CT.

5. Adrenal vein catheterization with aldosterone sampling (AVS): This is a procedure typically performed by experienced interventional radiologists at specialized centers and the gold standard in distinguishing between unilateral and bilateral causes of PA in patients where surgical treatment is possible and wanted with or without IV ACTH stimulation. Cortisol concentrations from the adrenal and peripheral veins are used to confirm successful catheterization of the adrenal veins (as the cortisol concentration is higher in the adrenal veins). Aldosterone concentrations from the 2 adrenal veins are then compared; aldosterone levels on the side of the tumor are much higher than on the contralateral side in unilateral disease.

In persons aged <35 years with confirmed PA, hypokalemia, aldosterone levels >831 pmol/L (>30 ng/dL), unilateral adrenal adenoma (>1-2 cm) on CT, and normal morphology of the contralateral adrenal gland, there is no need for AVS before qualifying for surgery.

6. Genetic testing for familial aldosteronism: Familial aldosteronism should be suspected in patients who developed hypertension and aldosteronism in early childhood, or in the case of a family history of aldosteronism in relatives who had hemorrhagic stroke at a young age.

Diagnostic Criteria

Diagnosis is based on low renin, inappropriately high aldosterone, and high ARR (value depends on assay) levels with or without confirmatory testing, as needed.

Subtype classification is done based on CT scan findings with or without AVS, as indicated, and with or without genetic testing, as indicated (as described above).

Differential Diagnosis

1. Other causes of mineralocorticoid-related hypertension (aldosterone and nonaldosterone mineralocorticoids): Table 6.1-3.

2. Other causes of hypokalemia.

3. Other causes of secondary hypertension.

TreatmentTop

Treatment goal: To normalize BP and serum potassium levels in order to prevent cardiovascular and renal morbidity.

Lifestyle Measures

Maintaining an appropriate body weight, moderate physical exercise, and diet with a restricted amount of sodium <100 mmol/day; the same applies to patients planned for surgical resection of adenoma.

Surgical Treatment

Unilateral laparoscopic adrenalectomy is the treatment of choice in APA and unilateral adrenal hyperplasia. If cortisol cosecretion is documented, it is important to cover the patient perioperatively with stress doses of glucocorticoids and taper them after surgery. Aldosterone levels should be checked the day after surgery, and potassium supplements and MRAs should be stopped; other antihypertensive agents can be stopped or tapered with monitoring of BP and potassium levels closely. There may be a state of transient (rarely permanent) hypoaldosteronism requiring liberal sodium intake, fluids, and fludrocortisone therapy for the first few weeks.

Pharmacotherapy

1. Potassium oral supplementation (may be tapered down once a mineralocorticoid receptor antagonist [MRA] is initiated and potassium level is adequate).

2. MRAs are indicated before the resection of an APA or UAH; as long-term management in patients with contraindications to surgery or those who do not want surgery; and in BAH/IHA, as they are most effective.

1) Spironolactone: Start with a dose of 12.5 to 25 mg daily and titrate up to a dose where potassium supplementation is not required to maintain normal levels (up to a max of 100 mg bid). Note that after several months the dose may need to be reduced again, even to low levels such as 25 mg bid. Adverse effects include gynecomastia (at doses >150 mg/d), erectile dysfunction, menstrual disorders caused by inhibition of androgens and progestogens, nausea, vomiting, and diarrhea.

2) Eplerenone is an alternative agent. It is more expensive but causes fewer adverse effects than spironolactone, as it is more specific. Start with a dose of 25 mg once daily. The dose may be increased to 100 mg/day (divided bid) initially and then titrated down once good BP control is achieved.

3) Other potassium-sparing diuretics: In case of spironolactone intolerance and unavailability of eplerenone, use amiloride 5 mg once daily to bid, up to 20 mg/d.

4) ACEIs/ARBs, DHP-CCBs, thiazide-like diuretics can be added to MRAs (or to another potassium-sparing diuretic) if hypertension persists. Beta-blockers are not very effective in this case.

5) Glucocorticoids are used in patients with GRA in addition to the above-listed drugs. The most frequently used agent is dexamethasone 0.5 to 0.75 mg/day.

PrognosisTop

Surgical resection of an APA or UAH leads to complete resolution of hypertension in 35% to 70% of patients as well as to normalized potassium levels in almost all patients.

If the disease is undiagnosed or inappropriately treated, the excess aldosterone—especially with a concomitant high salt intake—not only causes hypokalemia and hypertension but also has a direct adverse effect on cardiovascular and renal morbidity.

Many patients may have underlying essential hypertension even after resection of an APA or UAH and should be treated as per usual hypertension practices.

TablesTop

Table 6.1-1. Interpretation of the ARR

Renin measurement methods and units

Weak positive screening result

Strong positive screening result

Plasma renin activity (ng/mL/h)

ARR 550-750

ARR >750

Renin concentration (mIU/L)

ARR 60-90

ARR >90

Renin concentration (ng/L)

ARR 100-144

ARR >144

ARR, aldosterone-renin ratio. Aldosterone measured in pmol/L.

Table 6.1-2. Effects of medical states, other drugs, and antihypertensive agents on the ARR

False-positive results

– Aging

– CKD

– Beta-blockers

– Central alpha2 agonists (clonidine, methyldopa)

– NSAIDs

– Birth control pills

False-negative results

– Hypokalemia

– Pregnancy

– Diuretics

– ACEIs

– ARBs

– Ca2+ blockers (DHP)

– Direct renin inhibitors

Neutral

– Alpha1 blockers (doxazosin, terazosin, prazosin)

– Long-acting nondihydropyridine calcium channel blockers (verapamil and diltiazem)

– Hydralazine

ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARR, aldosterone-to-renin ratio; CKD, chronic kidney disease; DHP, dihydropyridine; NSAID, nonsteroidal anti-inflammatory drug.

Table 6.1-3. Causes of mineralocorticoid-dependent hypertension

Low renin, high aldosterone

Low renin, low aldosterone

High renin, high aldosterone

Primary aldosteronism

– Congenital adrenal hyperplasia: 17alpha-hydroxylase or 11beta‑hydroxylase deficit

– Apparent mineralocorticoid excess (11beta‑HSD2 deficit), genetic or acquired (eg, black licorice)

– DOC-secreting adrenal tumor

– Liddle syndrome

– Exogenous mineralocorticoid (eg, fludrocortisone)

– Cushing syndrome

– Primary cortisol resistance

– Renal artery stenosis

– Malignant hypertension

– Coarctation of the aorta

– Renin-secreting tumors (reninoma)

– High doses of diuretics

– Ectopic nonrenal renin-producing tumors

 

11beta‑HSD2, 11beta-hydroxysteroid dehydrogenase type 2; DOC, 11-deoxycorticosterone.

We would love to hear from you

Comments, mistakes, suggestions?

Partner

Industry Partners

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.